

Ikuo Sekine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7710400/publications.pdf>

Version: 2024-02-01

49
papers

540
citations

840776

11
h-index

713466

21
g-index

49
all docs

49
docs citations

49
times ranked

872
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics of Cancers in Adolescents and Young Adults Compared with Those in Adults in Their 60s: A Single-Center Experience. <i>Oncology</i> , 2022, 100, 140-147.	1.9	1
2	Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study. <i>BMC Cancer</i> , 2022, 22, 342.	2.6	2
3	Atherosclerotic cardiovascular events associated with immune checkpoint inhibitors in cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 659-664.	1.3	5
4	Echocardiography image quality of global longitudinal strain in cardio-oncology: a prospective real-world investigation. <i>Journal of Echocardiography</i> , 2022, 20, 159-165.	0.8	2
5	Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2022, 42, 2583-2590.	1.1	5
6	Malignant Pleural Mesothelioma in Patients Who Previously Received Radiotherapy for Their First Malignant Tumor. <i>Internal Medicine</i> , 2021, 60, 663-665.	0.7	0
7	Rationale, Design, and Feasibility of a Prospective Multicenter Registry Study of Anthracycline-Induced Cardiotoxicity (AIC Registry). <i>Journal of Clinical Medicine</i> , 2021, 10, 1370.	2.4	3
8	Long-term outcomes of high-dose (74 GyE) proton beam therapy with concurrent chemotherapy for stage III non-small-cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 1320-1327.	1.9	8
9	Squamous Cell Carcinoma of Unknown Primary: Multiple Skeletal Metastases Without Detectable Visceral Lesions. <i>Cureus</i> , 2021, 13, e16525.	0.5	0
10	Dramatic Recovery from Cardiovascular Collapse: Paclitaxel as an Urgent Treatment for Primary Cardiac Angiosarcoma. <i>Internal Medicine</i> , 2021, 60, 67-71.	0.7	1
11	Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice. <i>Anticancer Research</i> , 2020, 40, 5757-5764.	1.1	12
12	Cardiology consultation in oncology practice: a 5-year survey. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1419-1425.	1.3	6
13	Salvage Photon or Proton Radiotherapy for Oligo-recurrence in Regional Lymph Nodes After Surgery for Non-small Cell Lung Cancer. <i>In Vivo</i> , 2020, 34, 1883-1892.	1.3	4
14	Successful use of extracorporeal membrane oxygenation for airway-obstructing lung adenocarcinoma. <i>Thoracic Cancer</i> , 2020, 11, 3024-3028.	1.9	10
15	Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry. <i>Lung Cancer</i> , 2020, 146, 160-164.	2.0	6
16	Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database. <i>Lung Cancer</i> , 2020, 146, 236-243.	2.0	7
17	Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study. <i>Anticancer Research</i> , 2020, 40, 957-964.	1.1	7
18	A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients. <i>Cancer Science</i> , 2020, 111, 1685-1691.	3.9	22

#	ARTICLE	IF	CITATIONS
19	How to Advance Clinical Research. Japanese Journal of Lung Cancer, 2020, 60, 292-297.	0.1	0
20	A Prompt Diagnosis of Superior Vena Cava Obstruction Established by Physical Examination. Internal Medicine, 2019, 58, 3211-3212.	0.7	5
21	Small-Cell Lung Cancer Treatment of Newly Diagnosed Patients with Poor Performance Status. Case Reports in Oncology, 2019, 12, 613-620.	0.7	6
22	Serum Soluble Interleukin-2 Receptor as a Possible Biomarker for the Early Detection and Follow-up of Nivolumab-Induced Pneumonitis. Journal of Thoracic Oncology, 2019, 14, e90-e91.	1.1	7
23	AMPK activation induced in pemetrexed-treated cells is associated with development of drug resistance independently of target enzyme expression. Molecular Oncology, 2019, 13, 1419-1432.	4.6	9
24	Features of adolescent and young adult cancer patients in Japan.. Journal of Clinical Oncology, 2019, 37, e13081-e13081.	1.6	0
25	Immune checkpoint inhibitor-related myocarditis. Japanese Journal of Clinical Oncology, 2018, 48, 7-12.	1.3	57
26	Induction systemic therapy followed by surgery for stages II-III non-small cell lung cancer: steady efforts. Journal of Thoracic Disease, 2018, 10, S3942-S3945.	1.4	2
27	Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer. Case Reports in Oncology, 2018, 11, 622-632.	0.7	10
28	Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011). Lung Cancer, 2017, 108, 232-237.	2.0	7
29	Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. Japanese Journal of Clinical Oncology, 2017, 47, 678-682.	1.3	34
30	Cardiovascular toxic effects of targeted cancer therapy. Japanese Journal of Clinical Oncology, 2017, 47, 779-785.	1.3	13
31	Afatinib-Induced Severe Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy: A Case Report. Journal of Thoracic Oncology, 2017, 12, e11-e13.	1.1	4
32	Case reports of adverse drug reactions associated with nivolumab administration. Japanese Journal of Clinical Oncology, 2017, 47, 193-193.	1.3	2
33	Osimertinib-Induced Interstitial Lung Disease Presenting as Eosinophilic Pneumonia. Journal of Thoracic Oncology, 2017, 12, e118-e120.	1.1	13
34	Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways. BMC Cancer, 2017, 17, 309.	2.6	14
35	Cytotoxicity of replication-competent adenoviruses powered by an exogenous regulatory region is not linearly correlated with the viral infectivity/gene expression or with the E1A-activating ability but is associated with the p53 genotypes. BMC Cancer, 2017, 17, 622.	2.6	3
36	An image cytometric technique is a concise method to detect adenoviruses and host cell proteins and to monitor the infection and cellular responses induced. Virology Journal, 2017, 14, 219.	3.4	0

#	ARTICLE	IF	CITATIONS
37	Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells. <i>Cancer Cell International</i> , 2017, 17, 120.	4.1	1
38	Azathioprine combination therapy for steroid-refractory hepatic immune system-related adverse events. <i>European Journal of Dermatology</i> , 2017, 27, 301-303.	0.6	21
39	Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 175-178.	1.3	52
40	What is the optimal first-line treatment for advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer?. <i>Journal of Thoracic Disease</i> , 2017, 9, E447-E450.	1.4	0
41	Are there any differences in genomic characterization of non-small cell lung cancer between African Americans and Whites?. <i>Journal of Thoracic Disease</i> , 2016, 8, E1517-E1519.	1.4	1
42	Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 875-878.	1.3	70
43	Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma. <i>BMC Cancer</i> , 2016, 16, 455.	2.6	1
44	Safety of a short hydration method for cisplatin administration in comparison with a conventional method—a retrospective study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 370-377.	1.3	15
45	Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer. <i>Cancer Science</i> , 2016, 107, 315-319.	3.9	7
46	An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol. <i>SpringerPlus</i> , 2016, 5, 195.	1.2	8
47	Drug resistance originating from a TGF- β 2/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation. <i>International Journal of Oncology</i> , 2016, 48, 1825-1836.	3.3	62
48	A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene. <i>SpringerPlus</i> , 2015, 4, 358.	1.2	6
49	Phase II study of amrubicin at a dose of 45 mg/m ² in patients with previously treated small-cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 941-946.	1.3	9